Asparagine Specific Enzymes (Erwinaze, Rylaze, Oncaspar, Asparlas) Coverage Criteria
Customize your policy alerts
Sign up for Anthem Policy CC-0096 alerts
Get alerted when Policy CC-0096 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage criteria for asparagine specific enzymes (Erwinaze, Rylaze, Oncaspar, Asparlas) for treatment of acute lymphoblastic leukemia and select NK/T-cell lymphomas; applies to Anthem medical benefit reviews and prior authorization for covered members.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.